5th May 2026 13:30
Prolight Diagnostics AB (publ) has today published its Annual Report for the financial year 2025. The report is available via the attached file or on the Company’s website: https://prolightdx.com/en/investors/financial-reports/
For further information, please contact:Ulf Bladin, CEOE-mail: [email protected]Phone: +46 73 582 39 87Company website: www.prolightdx.com
About UsProlight Diagnostics AB develops innovative Point-of-Care systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood. We want to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Our launch product will be for the measurement of high sensitive troponin, to aid in the rule-in and rule-out of myocardial infarction. The company’s share is traded on the NGM Growth Market marketplace, under the ticker PRLD.
AttachmentsAnnual Report Prolight 2025
Related Shares:
Prolight Diagno